1-17 of 17
Brad Kahl, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

Chronic Lymphocytic Leukemia and a Pandemic: A Bad Combination

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2022) 19 (1)
https://doi.org/10.1182/hem.V19.1.202212
Published: 2022
Articles

Major Advances in Hairy Cell Leukemia

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (6)
https://doi.org/10.1182/hem.V18.6.202165
Published: 2021
Articles

Moving Beyond CHO(E)P for Peripheral T-cell Lymphoma

Neha Mehta-Shah, MD, Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (5)
https://doi.org/10.1182/hem.V18.5.202155
Published: 2021
Articles

A Prognostic Index for Burkitt Lymphoma

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (4)
https://doi.org/10.1182/hem.V18.4.202146
Published: 2021
Articles

Ibrutinib for the Treatment of Waldenström Macroglobulinemia: Some Mutations Are Better Than Others

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (3)
Published: 2021
Articles

A Predictive Biomarker in Lymphoma: Better Late Than Never

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2021) 18 (2)
Published: 2021
Articles

A New CAR-T Option for Mantle Cell Lymphoma

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 18 (1)
Published: 2020
Articles

Is Dose-adjusted EPOCH-R Enough in Burkitt Lymphoma?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 17 (6)
Published: 2020
Articles

S1826: U.S. Intergroup Trial for Advanced-Stage Hodgkin Lymphoma

Alex F. Herrera, MD, Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 17 (5)
Published: 2020
Articles

Are We Capable of Curing Follicular Lymphoma, But Just Afraid to Say It?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 17 (3)
https://doi.org/10.1182/hem.V17.3.10369
Published: 2020
Articles

Picking a Partner: As in Life, it Matters for MYC

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2020) 17 (2)
https://doi.org/10.1182/hem.V17.2.10279
Published: 2020
Articles

Frontline CLL Options: An Embarrassment of Riches?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 17 (1)
https://doi.org/10.1182/hem.V17.1.10148
Published: 2019
Articles

RIP FCR?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (6)
https://doi.org/10.1182/hem.V16.6.9931
Published: 2019
Articles

Is It Time for Time-limited Therapy in Frontline CLL?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (5)
https://doi.org/10.1182/hem.V16.5.9796
Published: 2019
Articles

Is Double-hit Diffuse Large B-cell Lymphoma More Common Than We Think?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (4)
https://doi.org/10.1182/hem.V16.4.9652
Published: 2019
Articles

Can We Use MRD Status to Personalize Therapy in Mantle Cell Lymphoma?

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (3)
https://doi.org/10.1182/hem.V16.3.9575
Published: 2019
Articles

Keeping Your ESCHELONs Straight

Brad Kahl, MD
Journal: The Hematologist
The Hematologist (2019) 16 (2)
https://doi.org/10.1182/hem.V16.2.9387
Published: 2019